MDP Technicals trying to retest 3rd time support near 1.48 and upon successful bounce back, it can jump above 3.5 easily. Some thing can be sensed here. Eps positve. So hope positive. Take your own decision and study before any blind call
0.30USD
1.19 MUSD
105.76 MUSD
22.00 M
About Medexus Pharmaceuticals Inc
Sector
CEO
Kenneth d’Entremont
Headquarters
Bolton
Website
Employees (FY)
98
Founded
2013
FIGI
BBG00J4WY5J4
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The firm products include IXINITY, Rasuvo, Metoject, Rupall, and Gleolan. The company was founded on December 10, 2013 and is headquartered in Bolton, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MEDXF is 1.17 USD — it has decreased by 3.98% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Medexus Pharmaceuticals Inc stocks are traded under the ticker MEDXF.
Medexus Pharmaceuticals Inc is going to release the next earnings report on Jun 19, 2024. Keep track of upcoming events with our Earnings Calendar.
MEDXF stock is 4.15% volatile and has beta coefficient of 0.74. Check out the list of the most volatile stocks — is Medexus Pharmaceuticals Inc there?
One year price forecast for Medexus Pharmaceuticals Inc has a max estimate of 4.34 USD and a min estimate of 1.49 USD.
MEDXF earnings for the last quarter are −0.05 USD per share, whereas the estimation was 0.02 USD resulting in a −378.71% surprise. The estimated earnings for the next quarter are 0.06 USD per share. See more details about Medexus Pharmaceuticals Inc earnings.
Medexus Pharmaceuticals Inc revenue for the last quarter amounts to 30.30 M USD despite the estimated figure of 30.36 M USD. In the next quarter revenue is expected to reach 30.74 M USD.
Yes, you can track Medexus Pharmaceuticals Inc financials in yearly and quarterly reports right on TradingView.
MEDXF stock has risen by 2.63% compared to the previous week, the month change is a 1.97% rise, over the last year Medexus Pharmaceuticals Inc has showed a 12.93% increase.
MEDXF net income for the last quarter is −548.76 K USD, while the quarter before that showed −1.08 M USD of net income which accounts for 49.15% change. Track more Medexus Pharmaceuticals Inc financial stats to get the full picture.
Today Medexus Pharmaceuticals Inc has the market capitalization of 28.92 M, it has decreased by 5.27% over the last week.
No, MEDXF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MEDXF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Medexus Pharmaceuticals Inc stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 98.00 employees. See our rating of the largest employees — is Medexus Pharmaceuticals Inc on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Medexus Pharmaceuticals Inc technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Medexus Pharmaceuticals Inc stock shows the sell signal. See more of Medexus Pharmaceuticals Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Medexus Pharmaceuticals Inc future price: according to them, MEDXF price has a max estimate of 4.34 USD and a min estimate of 1.49 USD. Read a more detailed Medexus Pharmaceuticals Inc forecast: see what analysts think of Medexus Pharmaceuticals Inc and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Medexus Pharmaceuticals Inc EBITDA is 18.95 M USD, and current EBITDA margin is 13.48%. See more stats in Medexus Pharmaceuticals Inc financial statements.